Erin Wilson
Stock Analyst at Morgan Stanley
(1.79)
# 3,135
Out of 4,876 analysts
22
Total ratings
46.15%
Success rate
0.75%
Average return
Main Sectors:
Stocks Rated by Erin Wilson
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RPD Rapid7 | Maintains: Equal-Weight | $26 → $28 | $22.70 | +23.35% | 7 | May 13, 2025 | |
| ALGN Align Technology | Maintains: Outperform | $715 → $732 | $188.52 | +288.29% | 3 | Jul 29, 2021 | |
| CRL Charles River Laboratories International | Maintains: Neutral | $352 → $385 | $150.01 | +156.65% | 1 | Jul 20, 2021 | |
| IQV IQVIA Holdings | Maintains: Outperform | $242 → $265 | $157.47 | +68.29% | 1 | Jul 20, 2021 | |
| MEDP Medpace Holdings | Maintains: Outperform | $200 → $205 | $310.69 | -34.02% | 1 | Jul 20, 2021 | |
| ICLR ICON Public Limited Company | Maintains: Outperform | $245 → $250 | $144.56 | +72.94% | 2 | Jul 20, 2021 | |
| ELAN Elanco Animal Health | Upgrades: Outperform | $33 → $38 | $14.29 | +165.92% | 1 | Feb 26, 2021 | |
| FLGT Fulgent Genetics | Downgrades: Underperform | n/a | $19.68 | - | 1 | Jan 8, 2021 | |
| TMO Thermo Fisher Scientific | Initiates: Neutral | $341 | $408.28 | -16.48% | 1 | Jan 22, 2020 | |
| INCR InterCure | Maintains: Outperform | $68 → $54 | $1.49 | +3,524.16% | 4 | Nov 14, 2017 |
Rapid7
May 13, 2025
Maintains: Equal-Weight
Price Target: $26 → $28
Current: $22.70
Upside: +23.35%
Align Technology
Jul 29, 2021
Maintains: Outperform
Price Target: $715 → $732
Current: $188.52
Upside: +288.29%
Charles River Laboratories International
Jul 20, 2021
Maintains: Neutral
Price Target: $352 → $385
Current: $150.01
Upside: +156.65%
IQVIA Holdings
Jul 20, 2021
Maintains: Outperform
Price Target: $242 → $265
Current: $157.47
Upside: +68.29%
Medpace Holdings
Jul 20, 2021
Maintains: Outperform
Price Target: $200 → $205
Current: $310.69
Upside: -34.02%
ICON Public Limited Company
Jul 20, 2021
Maintains: Outperform
Price Target: $245 → $250
Current: $144.56
Upside: +72.94%
Elanco Animal Health
Feb 26, 2021
Upgrades: Outperform
Price Target: $33 → $38
Current: $14.29
Upside: +165.92%
Fulgent Genetics
Jan 8, 2021
Downgrades: Underperform
Price Target: n/a
Current: $19.68
Upside: -
Thermo Fisher Scientific
Jan 22, 2020
Initiates: Neutral
Price Target: $341
Current: $408.28
Upside: -16.48%
InterCure
Nov 14, 2017
Maintains: Outperform
Price Target: $68 → $54
Current: $1.49
Upside: +3,524.16%